Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Fluvastatin Extended Release Tablets in Healthy Participants
NCT06830954Phase 1Not yet recruiting
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Feb 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of fluvastatin in hypercholesterolemia (2 arms), sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration and 1 more. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
fluvastatin
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT06830954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06830954.